로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > CNR1

CNR1

요약

Name:Cannabinoid CB1 receptor
Target Synonym:Cannabinoid Receptor 1 (Brain),CNR1,Cannabinoid Receptor 1,CANN6,CB-R,CNR,CB1,Central Cannabinoid Receptor,CB1K5,CB1A,CB1R,Receptor, Cannabinoid, CB1
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:21
Lastest Research Phase:Approved

제품 리스트 구매

제품 상태별:
제품 유형별 :
종별:
결합물별:
제품번호 제품 설명 구조 순도 특징
CN1-H52P6 Human Human CNR1 Full Length Protein (VLP)

일부의 생물활성 데이터

CN1-H52P6-ELISA
 CNR1 ELISA

Immobilized Human CNR1 Full Length Protein-VLP (Cat. No. CN1-H52P6) at 5 μg/mL (100 μL/well) can bind Human Anti-CNR1,Human IgG4 | Human Kappa with a linear range of 1-31 ng/mL (QC tested).

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cannabidiol GWP-42003-P; BOL-DP-o-05; GW-42003; RLS-103; LYT-310; RAD011; GWP-42003; BTX-1204; ZYN-002; PTL-101; CHI-902; APH-1501; AVCN-583601; GLA-015; BTX-1503; BTX-1801; BTX-1702; PBX-1308; ART-12.11; ART-1211; RAD-011; BRCX-014 Approved Gw Pharmaceuticals Plc Epidyolex, Cannepil, Epidiolex, Zygel United States Epilepsies, Myoclonic; Lennox Gastaut Syndrome Gw Research Ltd 2018-06-25 Peripheral Nervous System Diseases; Substance-Related Disorders; HIV Infections; Sleep Initiation and Maintenance Disorders; Ovarian Neoplasms; Facial Pain; Migraine Disorders; Marijuana Smoking; Tobacco Use Cessation; Tobacco Smoking; Acne Vulgaris; Anxiety; Seizures; Schizophrenia; Pain; Autism Spectrum Disorder; Rett Syndrome; Brain Injuries, Traumatic; Inflammatory Bowel Diseases; Tuberous Sclerosis; Fatty Liver; Marijuana Abuse; Chronic Pain; Marijuana Use; Alcoholic Intoxication; Diabetes Mellitus, Type 2; Child Behavior Disorders; Appetitive Behavior; Diabetic Neuropathies; Chronic Urticaria; Opioid-Related Disorders; Coronavirus Disease 2019 (COVID-19); Hoarding Disorder; Musculoskeletal Pain; Psychotic Disorders; Neoplasms; Bipolar Disorder; Arthritis, Rheumatoid; Graft vs Host Disease; Brain Diseases; Blepharospasm; Sturge-Weber Syndrome; Glioblastoma; Dyspepsia; Sleep Wake Disorders; Hyperalgesia; Parkinsonian Disorders; Pancreatic Neoplasms; Multiple Sclerosis; Lennox Gastaut Syndrome; Azotemia; U Details
Cannabidiol/Dronabinol THC-5; delta-9-THC/CBD; MPL-001; MPL-005; GW-1000; KL16-012; BOL-DP-o-04; GW-1000-02; PPP-001; MGC-ODT Approved Gw Pharmaceuticals Sativex, Qixleef Canada Muscle Spasticity; Multiple Sclerosis; Neuralgia; Cancer Pain; Chronic Pain null 2005-04-01 Arthritis, Psoriatic; Phobia, Social; Urinary Bladder, Overactive; Tic Disorders; Reflex Sympathetic Dystrophy; Huntington Disease; Sciatica; Muscle Spasticity; Malnutrition; Acute Pain; Tourette Syndrome; Neuromyelitis Optica; Dementia; Neuralgia; Panic Disorder; Stress Disorders, Post-Traumatic; Hepatic Insufficiency; Osteoarthritis, Knee; Back Pain; Drug Resistant Epilepsy; Hidradenitis Suppurativa; Agoraphobia; Renal Insufficiency, Chronic; Social Behavior; Low Back Pain; Cerebral Palsy; Corticobasal degeneration; Depression; Peripheral Nervous System Diseases; Sleep Initiation and Maintenance Disorders; Pain; Anxiety; Spinal Cord Injuries; Cancer Pain; Chronic Pain; Marijuana Use; Spasm; Renal Insufficiency; Squamous Cell Carcinoma of Head and Neck; Marijuana Abuse; Depressive Disorder, Major; Migraine Disorders; Neoplasms; Diabetic Neuropathies; Arthritis, Rheumatoid; Anxiety Disorders; Kidney Diseases; Anorexia; Essential Tremor; Opioid-Related Disorders; Neck Pain; Sleep Wake Disorders; Multiple Scler Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Dronabinol(Vertanical) VER-01 Phase 3 Clinical Vertanical GmbH Low Back Pain Details
Nimacimab RYI-018; RYI-028; JNJ-2463 Phase 2 Clinical Non-alcoholic Fatty Liver Disease; Diabetic Gastroparesis Details
IGC-AD1 IGC-AD1 Phase 2 Clinical University Of South Florida Depression; Anxiety; Alzheimer Disease; Psychomotor Agitation; Memory Disorders Details
Dronabinol(AXIM Biotechnologies) Phase 3 Clinical Axim Biotech Neoplasms; Vomiting; Child Nutrition Disorders; Nausea; Cachexia; Anorexia Nervosa; Sarcopenia Details
GFB-024 Phase 1 Clinical Takeda Pharma Kidney Diseases; Endocrine System Diseases; Diabetic Nephropathies; Diabetes Complications; Diabetes Mellitus Details
[11C]OMAR [11C]JHU-75528 Phase 1 Clinical Johns Hopkins University School Of Medicine Marijuana Abuse; Schizophrenia Details
ZYN-001 ZYN-001 Phase 1 Clinical Zynerba Pharmaceuticals Neuralgia; Fibromyalgia Details
Cannabidiol/Palmitoylethanolamide THX-210; SCI–210 Phase 2 Clinical Therapix Biosciences Ltd Autism Spectrum Disorder; Diabetic Neuropathies Details
DBPR-211 Phase 1 Clinical National Health Research Institutes Diabetes Mellitus, Type 2 Details
MP-10X MP-10X Clinical Medipure Holdings Pain Details
11C-MePPEP 11C-MePPEP Phase 2 Clinical Eli Lilly And Company Substance-Related Disorders; Obesity Details
AEF-0217 AEF-0217 Phase 2 Clinical Aelis Farma Down Syndrome Details
NEO-1940 AZD-1940; NEO-1940; ART-2713; ART27.13 Phase 1 Clinical Astrazeneca Plc, Neomed Inc, Pfizer Inc Sleep Initiation and Maintenance Disorders; Cancer Pain; Anxiety; Nausea; Cachexia Details
C20T5 C20T5 Murdoch Childrens Research Institute Details
Zevaquenabant MRI-1867; (S)-MRI-1867; INV-101 Phase 1 Clinical National Institutes Of Health Scleroderma, Systemic; Colitis, Ulcerative Details
Monlunabant MRI-1891; NN9440–INV-202; INV-202 Phase 2 Clinical Inversago Pharma Inc Metabolic Syndrome; Metabolic Diseases; Diabetic Nephropathies; Obesity Details
IPI 201(Isosceles Pharmaceuticals Inc ) IPI-201 Phase 1 Clinical Pain, Postoperative Details
V-24343 V-24343; ANEB-001 Phase 2 Clinical Vernalis Plc Poisoning; Obesity Details
AX-1602 AX-1602 Phase 2 Clinical Axim Biotech Psoriasis; Dermatitis, Atopic; Vitiligo Details
Cannabidiol/hydroxychloroquine IHL-675A; IHL-675 Phase 2 Clinical Incannex Healthcare Ltd Arthritis, Rheumatoid; Respiratory Distress Syndrome, Adult Details
AEF-0117 AEF-0117 Phase 2 Clinical National Institute On Drug Abuse, Aelis Farma Marijuana Abuse Details
Tetrahydrocannabivarin GWP-42004; THCV; O-4394; DELTA9-THCV; GW-42004 Phase 1 Clinical Gw Pharmaceuticals Plc Diabetes Mellitus, Type 2; Hyperglycemia; Metabolic Syndrome; Obesity, Morbid; Hypercholesterolemia; Dyslipidemias Details
C12T12 C12T12 Murdoch Childrens Research Institute Details

This web search service is supported by Google Inc.

totop